Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira once-weekly versus twice-weekly titration in insulin-naive adults with type 2 diabetes
2012-004625-25Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c. Started Jun 2014; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004625-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004625-25.